Drug Trial Radar · NCT05924815
Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval
Last checked: Nov 20, 2026Latest source record: Dec 19, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
44
Actual
Start
May 15, 2023
Primary completion
Nov 14, 2023
Study completion Nov 14, 2023
Sponsor
- Lead sponsor
- CytokineticsIndustry
- Sponsor type
- Industry
- First posted
- Jun 29, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double (participant, investigator)
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a single-center, 2-part (Part A and Part B) study in healthy participants. Part A (Dose Finding) is an open-label, SAD study to identify the dose for Part B. Part B (TQT Study) is a randomized, double-blind (with respect to aficamten and matching placebo), positive- and placebo-controlled, single-dose, 3-way crossover study to evaluate the effect of aficamten administration on QT/QTc interval.
Conditions
- Healthy Participants
Interventions
AficamtenDrug
Oral Tablet
Aficamten-matching PlaceboDrug
Oral Tablet
MoxifloxacinDrug
Oral Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: To determine the dose for Part BTime frame: Baseline to End of Study, up to 8 weeks
- Part B: placebo-corrected dQTcF for aficamtenTime frame: Baseline to End of Study, up to 14.5 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Celerion, Inc 2420
Tempe, Arizona
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.